Also, I realise the ‘chance’ factor to the equation ( the possible that the 3 participants may have been most likely to the CR ratio than others) , yet the same can be said about the next 3 participants on the escalating dose. Certainly a larger larger population study at this efficacy would make sense (to me anyway) outside the clouded reporting itself.
PTX Price at posting:
9.4¢ Sentiment: Buy Disclosure: Held
